Company Partners with Oxford University for Endometriosis Biomarker Diagnostic Test

Company Partners with Oxford University for Endometriosis Biomarker Diagnostic Test

MDNA Life Sciences is now partnering with the Oxford University in England to further develop and validate the Endometrial Mitomic Test, a noninvasive blood-based test based on the mitochondrial genome for the diagnosis of endometriosis.

Prof. Christian Becker and Prof. Krina Zondervan, co-directors of the Endometriosis Care and Research (CaRe) Centre, will be heading the new clinical study, which aims to discover new diagnostic approaches and identify novel treatments for endometriosis.

The Endometrial Mitomic Test is a blood-based screening test to detect endometriosis in high-risk patients and women of reproductive age. Now, in the new study, the researchers will be using MDNA’s proprietary Mitomic Technology and isolate blood-circulating mitochondrial biomarkers that identify women with and without the condition.

The test may provide physicians with a noninvasive, nonsurgical, highly accurate alternative to detect endometriosis and accelerate treatment initiation. Upon positive results of this study, the test should be launched in 2017.

“This collaborative effort between MDNA Life Sciences and the Endometriosis CaRe Centre is an exciting novel project aiming to identify urgently needed biomarkers in endometriosis focusing on mitochondrial DNA,” Becker said in a press release.

Becker, in collaboration with Zondervan, has worked with the World Endometriosis Research Foundation (WERF) in the Endometriosis Phenome and Biobanking Harmonization Project (EPHect). This study generated the current standards for research in endometriosis.

“Using the WERF EPHect data and sample collection protocols will ensure the highest standards of phenotypic data and biological sample quality, which is a prerequisite for high quality and reproducible studies,” Zondervan, said.

MDNA’s Mitomic Technology platform uses mitochondrial DNA and its properties to discover biomarkers, to identify diseases in their early stage, monitoring, risk assessment, and provide a target for potential therapies.

MDNA Life Sciences’ innovative platform has led to the discovery of various biomarkers for prostate, ovarian, lung, and pancreatic cancer, as well as other diseases.

“Particularly for endometriosis, which affects 10 percent of women of childbearing age and currently relies on an invasive surgical procedure for diagnosis, there is significant value in the development of a non-invasive molecular test,” said Chris Mitton, CEO of MDNA Life Sciences.

“The combination of our Mitomic Technology with the high quality, well-documented clinical specimens from the University of Oxford provides a powerful advantage for our efforts to develop enhanced diagnostic and screening tools for this high burden disease,” he said.